Navigation Links
Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
Date:11/3/2011

THE WOODLANDS, Texas, Nov. 3, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Dr. David Powell, senior vice president of metabolism research, will present data from clinical and preclinical studies of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), at the Cambridge Healthtech Institute's Diabetes Drug Discovery conference in Boston, Massachusetts on Friday, November 4, 2011.

In clinical studies to date, LX4211 has demonstrated a favorable safety profile and beneficial effects on multiple parameters of glycemic control and cardiovascular health.  Recent studies in healthy subjects have shown that LX4211 substantially decreases postprandial glucose levels without hypoglycemia and substantially reduces triglycerides, results that have not been reported for SGLT2-selective inhibitors.  Data from a mechanistic study in patients with type 2 diabetes demonstrated that a single dose of LX4211 significantly increased circulating levels of GLP-1 (active and total) and PYY, important regulators of glycemic and appetite control.  In addition, postprandial release of GLP-1 and PYY from the gastrointestinal (GI) tract has been observed in preclinical studies of SGLT1 knockout mice but not in SGLT2 knockout mice, indicating that inhibition of SGLT1 function may trigger the postprandial release of these important regulators of glycemic and appetite control.

For more information on this program or to download a copy of the presentation, please visit www.lexpharma.com.

About Lexicon
Lexicon is a biopharmaceutical company focused on disco
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Concord Medical Services Holdings ... CCM ), a leading specialty hospital management solution provider ... diagnostic imaging centers in China , ... of Directors declared a special cash dividend of US$0.30 ... ("ADS")) on the Company,s outstanding ordinary shares. The total ...
(Date:7/28/2014)... July 28, 2014 ... 2,5 Millionen £ investiert hat, um die ... Gesundheits-, Pharma- und Logistikbranche zu erfüllen. Albion ...      (Photo: http://photos.prnewswire.com/prnh/20140728/697982 ) ... OmPrompt sein beschleunigtes Wachstum mit Investitionen in ...
(Date:7/28/2014)... NEW PROVIDENCE, N.J. , July 28, 2014 /PRNewswire/ ... meet with Linde,s Healthcare division experts at the ... at McCormick Place in Chicago, Illinois ... nothing less than complete confidence in a reliable medical ... Segment manager. "Linde understands the importance of this critical ...
Breaking Medicine Technology:Concord Medical Declares Special Dividend 2OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2
... Ill. and LONDON, Sept. 23 Following today’s announcements ... the European Medicines Agency (EMA) for rosiglitazone in the ... Takeda Pharmaceuticals Europe Limited (“Takeda”) underscore the company’s commitment ... and to the millions of people living with type ...
... Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two ... of 1,800 Real-World Patients Compared XIENCE V to the Newer-Generation TAXUS® Liberte®,-- ... Performance in Key Safety and Efficacy... -- ABBOTT PARK, Ill., Sept. 23 ... ...
Cached Medicine Technology:Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 2Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 3Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 4Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 2Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 3Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 4Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 5Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 6Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 7Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 8Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 9
(Date:7/28/2014)... divide unless there is enough oxygen present to support ... types circumvent this rule. Researchers at The Johns Hopkins ... cells, warning signals, enabling cancers to continue to divide ... the researchers found that lysosomes the cell,s protein ... also uncovered new evidence that certain drugs can halt ...
(Date:7/28/2014)... Parker Waichman LLP, a personal injury law firm ... heroes of 9/11 are never forgotten, comments that the September ... According to a VCF message dated July 3, ... or before October 12, 2012 must file a Registration Form ... who were allegedly injured by the toxic dust cloud that ...
(Date:7/28/2014)... York, NY (PRWEB) July 28, 2014 ... literacy organization that has donated more than 200,000 books ... in 2001, announces the launch of Brooke’s Cooks, a ... values, while encouraging healthy living among at-risk children and ... Cooks will include a series of nutrition information workshops, ...
(Date:7/28/2014)... Utah (PRWEB) July 28, 2014 Bariatric ... and drinks, announced that it will be introducing three ... of products this summer. The additional flavors include: , ... pure taste-free protein , Inspire Pomegranate Razz Berry -­ ... flavor of soft-serve vanilla cone , Bariatric Eating's ...
(Date:7/28/2014)... one of two dopamine-producing regions in the brain was ... isoflurane or propofol. In the August issue of ... report that rats anesthetized with continuous doses of either ... up in response to electrical stimulation delivered to the ... major dopamine-releasing area, the substantia nigra, did not induce ...
Breaking Medicine News(10 mins):Health News:Cell's recycling center implicated in division decisions 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 4Health News:Bariatric Eating Announces Three New Protein Shake Flavors 2Health News:Stimulation of brain region restores consciousness to animals under general anesthesia 2
... By Steven Reinberg HealthDay Reporter , ... have prostate cancer that,s considered "intermediate risk," radiation plus ... a new study finds. This combination of treatments, ... prostate cancer or advanced disease, the researchers said. Men ...
... cardiologists are prone to misinterpreting electrocardiograms when using ... heart defects that could make exercising perilous, according ... School of Medicine and Lucile Packard Children,s Hospital. ... acumen of pediatric cardiologists from several health-care institutions ...
... HealthDay Reporter , WEDNESDAY, July 13 (HealthDay News) -- ... infection can significantly reduce the chance they will develop the ... is an extremely exciting finding for the field of HIV ... a University of Washington associate professor of global health. ...
... , WEDNESDAY, July 13 (HealthDay News) -- Rural workers are often ... loved one and their jobs, researchers report. According to ... University of New Hampshire, people who work in rural communities have ... lost pay or lost jobs and caring for themselves or a ...
... control, growing wildly and breaking all the rules of orderly ... is a balance between a cancer cell,s revved-up metabolism and ... depends on a hyperactive metabolism to fuel its rapid growth, ... reactive oxygen species (ROS) generated by such high metabolic demand. ...
... WEDNESDAY, July 13 (HealthDay News) -- Wearing flip-flops and baseball ... warns. "Most skin cancers occur on the parts of ... Rebecca Tung, director of the dermatology division at Loyola University ... release. "The problem with flip-flops and baseball caps is ...
Cached Medicine News:Health News:For Some Prostate Cancer Patients, Combo Treatment Improves Survival 2Health News:For Some Prostate Cancer Patients, Combo Treatment Improves Survival 3Health News:Pediatric cardiologists not always accurate in interpreting ECG results for young athletes 2Health News:Pediatric cardiologists not always accurate in interpreting ECG results for young athletes 3Health News:Drugs May Prevent HIV Spread Among Heterosexuals 2Health News:Drugs May Prevent HIV Spread Among Heterosexuals 3Health News:Rural Workers Often Lack Access to Sick Leave 2Health News:Taking out a cancer's co-dependency 2Health News:Taking out a cancer's co-dependency 3Health News:Flip-Flops, Baseball Caps May Raise Risk of Skin Cancer 2
Binocular indirect ophthalmic lenses. General diagnosis & treatment....
Binocular indirect ophthalmic lenses. Ultra-High resolutions viewing of posterior pole....
... super series slit ... Variable retinal scanning ... fundus diagnostic capability, ... potential field of ...
Volk indirect lenses. Wide field retinal diagnosis & treatment....
Medicine Products: